

CHILE

Number of new cases

59 876

Number of deaths


31 440

Number of prevalent cases (5-year)

169 882


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	9 495 704	9 754 488	19 250 192
Incidence*			
Number of new cancer cases	32 800	27 076	59 876
Age-standardized incidence rate	221.7	165.1	188.7
Risk of developing cancer before the age of 75 years (cum. risk %)	22.2	16.3	19.1
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Stomach	Breast Colorectum Lung	Prostate Colorectum Breast
Mortality*			
Number of cancer deaths	16 897	14 543	31 440
Age-standardized mortality rate	107.8	77.6	90.1
Risk of dying from cancer before the age of 75 years (cum. risk %)	10.7	8.1	9.3
Top 3 leading cancers (ranked by deaths)**	Prostate Stomach Lung	Breast Colorectum Lung	Lung Stomach Colorectum
Prevalence*			
5-year prevalent cases	92 089	77 793	169 882




Top 5 most frequent cancers**


Males



Females



Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Prostate	9 678	29.5%
2nd	Colorectum	3 351	10.2%
3rd	Stomach	3 350	10.2%
4th	Lung	2 619	8.0%
5th	Kidney	1 490	4.5%
-	Others	12 312	37.5%

Number of new cases in 2022, males, all ages

Rank	Cancer site	Number of cases	Percent
1st	Breast	5 640	20.8%
2nd	Colorectum	3 427	12.7%
3rd	Lung	1 772	6.5%
4th	Stomach	1 605	5.9%
5th	Cervix uteri	1 559	5.8%
-	Others	13 073	48.3%

Number of new cases in 2022, females, all ages

Rank	Cancer site	Number of cases	Percent
1st	Prostate	9 678	16.2%
2nd	Colorectum	6 778	11.3%
3rd	Breast	5 640	9.4%
4th	Stomach	4 955	8.3%
5th	Lung	4 391	7.3%
-	Others	28 434	47.5%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	9 678	1	16.2	7.3	2 703	4	8.6	1.1	36 539	384.8
Colorectum	6 778	2	11.3	2.3	3 330	3	10.6	0.96	20 588	107.0
Breast	5 640	3	9.4	4.1	1 775	6	5.6	1.1	22 677	232.5
Stomach	4 955	4	8.3	1.6	3 924	2	12.5	1.2	6 583	34.2
Lung	4 391	5	7.3	1.6	3 944	1	12.5	1.4	5 340	27.7
Kidney	2 233	6	3.7	0.88	1 052	9	3.3	0.36	7 075	36.8
Gallbladder	1 917	7	3.2	0.68	1 236	8	3.9	0.43	2 495	13.0
Pancreas	1 899	8	3.2	0.63	1 793	5	5.7	0.59	1 646	8.6
Bladder	1 635	9	2.7	0.53	742	14	2.4	0.19	5 224	27.1
Liver	1 623	10	2.7	0.56	1 572	7	5.0	0.54	1 824	9.5
NHL	1 569	11	2.6	0.59	753	13	2.4	0.25	5 187	27.0
Cervix uteri	1 559	12	2.6	1.1	825	11	2.6	0.54	5 376	55.1
Leukaemia	1 432	13	2.4	0.50	879	10	2.8	0.28	4 497	23.4
Thyroid	1 106	14	1.8	0.42	170	20	0.54	0.04	4 209	21.9
Corpus uteri	1 026	15	1.7	0.81	308	18	0.98	0.21	4 027	41.3
Melanoma	962	16	1.6	0.37	290	19	0.92	0.09	3 586	18.6
Ovary	932	17	1.6	0.72	583	16	1.9	0.43	2 900	29.7
Multiple myeloma	885	18	1.5	0.34	599	15	1.9	0.21	2 613	13.6
Oesophagus	844	19	1.4	0.23	759	12	2.4	0.19	944	4.9
Testis	822	20	1.4	0.58	108	23	0.34	0.08	3 446	36.3
Brain CNS	727	21	1.2	0.28	556	17	1.8	0.22	2 972	15.4
Lip, oral cavity	349	22	0.58	0.12	151	22	0.48	0.05	1 093	5.7
Hodgkin lymphoma	290	23	0.48	0.11	86	24	0.27	0.03	1 116	5.8
Larynx	245	24	0.41	0.08	164	21	0.52	0.05	761	4.0
Vulva	127	25	0.21	0.07	64	27	0.20	0.02	358	3.7
Oropharynx	124	26	0.21	0.05	66	26	0.21	0.02	360	1.9
Salivary glands	118	27	0.20	0.04	49	28	0.16	0.01	378	2.0
Penis	98	28	0.16	0.08	43	29	0.14	0.03	327	3.4
Mesothelioma	80	29	0.13	0.03	75	25	0.24	0.03	101	0.52
Hypopharynx	64	30	0.11	0.02	32	30	0.10	0.01	115	0.60
Vagina	57	31	0.10	0.04	25	31	0.08	0.02	149	1.5
Kaposi sarcoma	39	32	0.07	0.02	19	33	0.06	0.01	124	0.64
All cancers	59 876	-	-	19.1	31 440	-	-	9.3	169 882	-
All cancers excl. NMSC	57 082	-	-	18.5	31 154	-	-	9.3	160 587	-

Data source and methods

Incidence

Country-specific data source: No data
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)



Mortality

Country-specific data source: National (WHO)
 Method: National rates projected to 2022

[Click here to see detailed data source and methods](#)

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)
 ** NMSC included in other cancers
 Age standardization using world population ([see link](#))

References

Website citation
 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

